1.
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma
2.
3.
4.
De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study
5.